Anti-TNF therapy

Phase 3Small molecule

Takeda

Anti-TNF therapy is one of 135 small molecule programs targeting Necrosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

NecrosisActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Ulcerative ColitisActive, not recruiting

NecrosisPreclinical

Active, not recruiting

Inflammatory Bowel DiseasePreclinical

Active, not recruiting

Rheumatoid ArthritisPhase 3

Active, not recruiting

Ulcerative ColitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Anti-TNF therapy

Takeda

Phase 3

2 2

Orencia

Bristol-Myers Squibb

Preclinical

47 3

Actemra

Enbrel

64 5

Arcoxia

Novartis

Preclinical

4 6

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

14 7

Celexa

AbbVie

Preclinical

1 8

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 9

Rituxan

Pfizer

Preclinical

7 10

Cimzia

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Rheumatoid Arthritis

NCT04870203

Q4 2027

N/ARecruiting

Ulcerative Colitis

NCT06896305

Q3 2029

Post-ApprovalRecruiting

Crohn's Disease

NCT05781152

Clinical

Trials by Indication[1]

Rheumatoid Arthritis2 trials

Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Rheumatoid Arthritis

Unknown status·BBarts & The London NHS Trust··NCT02528292·24 enrolled

Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Active, not recruiting·UUniversity Hospital, Bordeaux·Phase 3·NCT04870203·160 enrolled

Ulcerative Colitis1 trial

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Recruiting·IIRCCS Ospedale San Raffaele·N/A·NCT06896305·80 enrolled

Inflammatory Bowel Disease1 trial

Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

Completed· Takeda logo

Takeda··NCT03090139·1,731 enrolled

Crohn's Disease1 trial

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

Recruiting·—·Phase 4·NCT05781152·900 enrolled

Necrosis1 trial

T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade

Completed·IImperial College London··NCT01060098·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Anti-TNF therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-TNF therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-TNF therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Takeda

Anti-TNF therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q3 2029

Trials by Indication[1]

Rheumatoid Arthritis2 trials

Ulcerative Colitis1 trial

Inflammatory Bowel Disease1 trial

Crohn's Disease1 trial

Necrosis1 trial

References

Drug Info

Quick Facts

Related News